Results 121 to 130 of about 44,168 (180)

Validation of ELN 2024 genetic classification in patients with AML treated with HMA-based regimens: PETHEMA registry study. [PDF]

Blood Neoplasia
Barragán E, Gil JV, Ayala R, Chillón C, Soria E, Bilbao C, Larráyoz MJ, Prados de la Torre E, Solana A, Martínez-Cuadrón D, Rodríguez-Veiga R, Rodríguez-Arbolí E, Tormo M, Martínez P, Lavilla E, García-Garay MC, Arce O, Bergua J, Serrano J, Botella C, Lacalzada C, Almela-Gallego A, Lopez-Lorenzo JL, Valero M, Ibañez F, Foncillas MÁ, Rodriguez-Medina C, Olave M, Gómez-Correcha KG, Calderón MT, Bernal T, Labrador J, Oliva A, Madrigal MD, Hermosín L, Amador L, García-Belmonte D, Herrera P, Vives S, Perez-Encinas M, Algarra L, Casado S, Martínez-Chamorro C, Polo M, Balerdi A, Roldán A, Couto C, Pereiro M, Vanegas R, Llop M, Sargas C, Cionfrini A, Mendizábal Y, Sánchez J, Calasanz MJ, Gómez-Casares MT, Pérez-Simón JA, García-Sanz R, Martínez-López J, Montesinos P, PETHEMA group.   +60 more
europepmc   +1 more source

Resistance to Targeted Therapy in AML: Current Challenges and Emerging Treatment Strategies. [PDF]

J Clin Med
Stafylidis C, Diamantopoulos PT.
europepmc   +1 more source

Von Economo Neuron Loss in Frontotemporal Dementia: A Meta-Analysis of Neuropathological Studies. [PDF]

Ann Clin Transl Neurol
Talmasov D, Santillo AF, Hof PR.
europepmc   +1 more source

Population Pharmacokinetic Analyses and Exposure-Efficacy Relationships of Venetoclax in Chinese Pediatric Patients with Hematological Malignancy in a Real-World Setting. [PDF]

Drug Des Devel Ther
Zhao Y, Song X, Zhang L, Zhu Y, Chen J, Gong Y, Luo X, He H, Zhang X, Huang L.   +9 more
europepmc   +1 more source

Prognostic Model Combining Mutational and Cytogenetic Profiles in Acute Myeloid Leukemia Treated with Venetoclax and Hypomethylating Agents. [PDF]

Blood Cancer Discov
Drekolias D, Tuz Zahra F, Fileni C, Sallman DA, Mo Q, Chan O, Zhang L, Vincelette ND, Yu X, Sammut R, Moon J, Park J, Umasangtongkul SA, Lledo FM, Razabdouski TN, Cheng CH, Qin D, Mai K, Ball S, Shallis RM, Xie Z, Kuykendall AT, Padron E, Sweet K, Walker AR, Komrokji RS, Lancet JE, Niyongere S, Cluzeau T, Yun S.   +29 more
europepmc   +1 more source

Selinexor and Venetoclax Combination in Patients With Relapsed or Refractory Acute Myeloid Leukemia. [PDF]

Am J Hematol
Ball S, Awan FT, Tomlinson BK, Stopczynski T, Fischer MA, Zhao Z, Fedorov K, Kishtagari A, Mohan SR, Ayers GD, Byrne MT, Savona MR.   +11 more
europepmc   +1 more source

Integrating Targeted Therapies into AML Frontline Therapy: Who Gets What and What Does the Future Hold? [PDF]

Cancers (Basel)
Schreiber J, Hopfinger G, Gleixner KV.
europepmc   +1 more source

The impact of venetoclax treatment duration on efficacy and hematologic toxicity in acute myeloid leukemia: a systematic review and meta-analysis. [PDF]

Ann Hematol
Pan Y, Shen Y, Miao S, Yao C, Zhai Z, Tao Q, Dong Y, Hu L.   +7 more
europepmc   +1 more source

Treatment-emergent coagulopathy during azacitidine/venetoclax induction in AML. [PDF]

Blood Neoplasia
Iyer SG, Deng R, Jurcic JG, Varabyeva A, May BL, Fernando S, Lipsky A, Lamanna N, Rosenblat TL, Kasbekar M, Viny AD.   +10 more
europepmc   +1 more source

A STAT3 degrader demonstrates efficacy in venetoclax resistant acute myeloid leukemia. [PDF]

Leukemia
Chakraborty S, Morganti C, Zaldana K, Rivera Pena B, Zhang H, Verma D, Gitego N, Ma F, Aluri S, Pradhan K, Gordon-Mitchell S, Mantzaris I, Goldfinger M, Feldman E, Gritsman K, Shi Y, Hubner S, Qiu YH, Brown BD, Khasawneh A, Skwarska A, de Camargo Magalhães ES, Verma A, Konopleva M, Tabe Y, Gavathiotis E, Colla S, Gollob J, Dey J, Kornblau SM, Koralov SB, Ito K, Shastri A.   +32 more
europepmc   +1 more source